At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Investigating Cognitive Function for Patients Participating in the SOFT Trial in Selected Centers
In Brief
A Phase 3 clinical trial evaluating Tamoxifen, triptorelin, and 1 other intervention for Breast Cancer and 2 related conditions. Completed, enrolled 86 participants across 15 sites in 2 countries.
Detailed Summary
RATIONALE: Learning about the long-term effects of adjuvant tamoxifen (T), adjuvant tamoxifen with ovarian function suppression (T+OFS), and exemestane with ovarian function suppression (E+ OFS) on brain function may help doctors plan cancer treatment. PURPOSE: This study is looking at brain function in premenopausal women who are receiving adjuvant tamoxifen (T) alone against those receive adjuvant tamoxifen (T+OFS) or exemestane (E+OFS) with ovarian function suppression (OFS) for early-stage breast cancer on clinical trial IBCSG-2402.